For over 35 years, Purolite has supplied specialty ion exchange resin technology to industries within complex regulatory environments, including biotechnology, pharmaceutical, food, fine chemical and electric power generation. Purolite is the only global company to focus 100% on resin technology.
Ensuring reliable availability of products in case of emergency is vital to customers and of paramount importance to Purolite.
As a leading supplier of resin media to the world’s most regulated industries, Purolite has a real-world security-of-supply system in place to support your process requirements for business continuity in the instance of natural disaster or emergency.
Purolite has manufacturing facilities at 3 strategic global locations in the USA, Asia and Europe, and is currently building its 4th manufacturing plant in the UK. This facility will be the second largest agarose manufacturing plant globally, with a capacity of 100,000 L per annum.
Currently, approximately 90% of all biopharmaceuticals approved by the U.S. Food and Drug Administration utilise a single source of agarose resins from a single manufacturing site, presenting a security of supply risk to long-term clinical trial material production.
Purolite have addressed this industry-wide concern by providing the first proven and reliable alternative source of agarose resins, allowing customers to dual-source their products to mitigate their supply risks.